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NEURAL REGENERATION RESEARCH 
PERSPECTIVE
Autophagy inhibition: a new 
therapeutic target in spinal muscular 
atrophy
Spinal muscular atrophy (SMA) is a hereditary pediatric motor neuron 
(MN) disease: survival motor neuron 1 (SMN1) gene mutation deter-
mines MN degeneration and, consequently, muscle atrophy, breathing 
and swallowing difficulties, and, in the most severe cases, premature 
death. A second unaffected gene (SMN2) is present, but it can only pro-
duce a limited amount of functional protein, modulating the disease se-
verity and progression. SMN, ubiquitously expressed, is mainly involved 
in the assembly of small nuclear ribonucleoproteins and pre-mRNA 
splicing requirements (Lunn and Wang, 2008). Its reduction determines 
selective MN loss: the type of cell death leading to neurodegeneration 
remains debated, since evidence of both increased apoptosis and dysreg-
ulated autophagy have been reported in SMA (Garcera et al., 2013).
Autophagy is an important intracellular process whereby cytoplasmic 
contents are delivered by double-membrane vesicles, called autopha-
gosomes, to the lysosomes for degradation. This process is highly reg-
ulated by a series of proteins called autophagy-related (ATG) proteins. 
Autophagic pathway controls degradation of cargo material such as 
damage mitochondria, damaged organelles, invading pathogens and 
aggregate-prone proteins. However, increasing evidence underscore the 
relevance of autophagy in neuronal physiology and the involvement of 
autophagy-lysosomal dysfunction in neurodegenerative disorders. In-
tracellular accumulation and aggregation of misfolded proteins, which 
are degraded by the autophagy-lysosomal system, are reported in several 
pathological phenotypes of most late-onset neurodegenerative disor-
ders (reviewed in Menzies et al., 2017). On one hand, the activation of 
autophagy may be protective in some neurodegenerative diseases by the 
clearance of toxic proteins, on the other, its over-activation or altered 
activity may perturb cell homeostasis and lead to cellular death.
Concerning SMA, some in vitro and in vivo studies have reported 
an increase of autophagic features in SMA MNs (Periyakaruppiah et 
al., 2016), suggesting that autophagy dysregulation can represent a new 
pathogenetic hypothesis in SMA and its pharmacological manipulation 
could influence the progression of the disease.
Involvement of autophagy in MN death in a mouse model of SMA: In 
order to investigate the role of autophagy in SMA, we used the SMNdel-
ta7 mouse, the most widely used and best-characterized murine model 
(SMN2+/+; SMNdelta7+/+; SMN–/–), with an average lifespan of 13 days. In 
our work (Piras et al., 2017), we confirmed the increased expression of 
autophagic markers, Beclin 1 and microtubule-associated protein 1 light 
chain 3-II (LC3-II), by western blot analysis and, furthermore, immu-
nofluorescence staining and electron microscopy studies demonstrated 
an increased number of autophagic vesicles (AVs) in the lumbar MNs of 
SMA pups. In addition, to evaluate the autophagic activity, we analyzed 
the level of p62/SQSTM1, which is selectively degraded by the autopha-
gosomes, observing that it was unchanged in the spinal cord of SMA 
compared to the control group. Altogether these results suggested that 
the autophagic flux was unaffected, thus hypothesizing that the accumu-
lation of non-functional AVs may lead the neurodegeneration in the spi-
nal cord of SMA (Figure 1). Moreover, we observed an increased level of 
cleaved Caspase-3 and reduced expression of Bcl2 (respectively, pro- and 
anti-apoptotic markers), confirming an involvement of the apoptotic cell 
death in the SMNdelta7 mouse model as previously reported in human 
patients and other in vivo SMA models (Figure 1).
However, so far no studies were conducted to address the direct role 
of autophagy in SMA and its pharmacological modulation in order to 
influence the disease progression. Several previous reports demonstrated 
that inhibition of autophagy by 3-methyladenine (3-MA) delayed neu-
ronal loss in different mouse model of neurodegenerative disorders (e.g., 
Alzheimer’s disease, Parkinson’s disease and Frontotemporal dementia) 
and ischemia (reviewed in Jaeger and Wyss-Coray, 2009).
Thus, we evaluated the effect of the intracerebroventricular (ICV) 
administration of 3-MA in our SMA model (Figure 2A) (Piras et al., 
2017). We observed decreased levels of autophagic markers (Beclin 1 
and LC3-II) and reduction of AVs in the lumbar spinal cord after 3-MA 
treatment. In accordance with these results, the protein levels of p62/
SQSTM1 were increased. Altogether these results confirmed the effects 
of 3-MA in the suppression of the autophagosome formation and au-
tophagic activity in the lumbar spinal cord of SMA pups. Interestingly, 
we found that 3-MA administration reduced apoptotic cell death in the 
lumbar spinal cord, underlying the important relationship between auto-
phagy and apoptosis. Therefore, we performed stereological MN counts 
observing that ICV administration of 3-MA improved MN survival in 
the lumbar spinal cord. Interestingly, inhibition of autophagy slightly, 
but significantly, increased the lifespan of SMA pups, and delayed the 
decrease in motor performance, in comparison to the control group 
treated with saline (Figure 2A).
Future prospective 
Autophagy manipulation: therapeutic opportunities: Our observations 
strongly highlight the involvement of autophagy in SMA. We suggest 
for the first time that inhibition of this process by ICV administration of 
3-MA have a significant impact on disease progression, making autoph-
agy a novel and intriguing therapeutic target.
In agreement with previous in vivo and in vitro studies (Garcera et al., 
2013; Periyakaruppiah et al., 2016), we demonstrated an increase level 
of autophagosomes in the cytoplasm of MNs. In addition, since auto-
phagosome accumulation may affect the normal intracellular trafficking 
[finally causing direct or indirect cytotoxicity (Figure 1)], we speculated 
that reducing autophagosome formation may improve MN survival in 
our mouse model of SMA.
Moreover, our results suggested that repeated administrations of 
3-MA were necessary to consistently delay the motor performance 
worsening in SMA pups compared to a single dose (Piras et al., 2017), 
thus suggesting that a prolonged therapy should be more indicated and 
necessary.
However, in this context, caution should be adopted in the applica-
tion of 3-MA: it inhibits autophagy acting temporally on class III phos-
phadylinositol 3-kinase (PtdIns3K) and, on the contrary, it can equally 
promote autophagy especially after prolonged exposure by its action on 
the class I PtrIns3K. Thus, in a translational perspective, we suggest the 
use of tested molecules that directly modulate autophagy pathway with 
higher specificity, e.g. LYR294002 and Wortmannin (as discussed in 
Piras et al., 2017). As an alternative, genetic manipulation of autophagic 
genes could represent a potential strategy to modify the disease progres-
sion and pathogenesis, as already reported for other neurodegenerative 
disorders (reviewed in Loera-Valencia et al., 2018).
Overall, our work strongly suggests that autophagy inhibition plays a 
protective role in SMA and, on the contrary, drugs that induce autopha-
gosome formation should be avoided for the treatment of SMA. Howev-
er, additional studies are needed before clinical translation because, for 
example, manipulation of autophagy in the pathogenesis of amyotrophic 
lateral sclerosis (ALS, another MN disease) has been extensively investi-
gated in recent years showing controversial results (Ramesh and Pandey, 
2017). Indeed, preclinical studies on ALS models suggest that activation 
of autophagy represents a possible therapeutic target: several compounds 
promoting autophagy, e.g., rapamycin, lithium, and trehalose decrease 
aberrant protein aggregation in ALS. On the other hand, contradictory 
evidence has shown that rapamycin can worsen MN degeneration and 
decrease lifespan in a mouse model of ALS (Ramesh and Pandey, 2017).
In summary, all these results demonstrated that the autophagic pro-
cess should be finely modulated in MN degenerative disorders, since it 
probably implicates a delicate balance between numerous molecules/
mechanisms that, being detrimental or beneficial, retain opposing 
effects. 
Genetic manipulation targeting SMN alternative splicing and combina-
torial approaches: When several years ago the molecular genetic causes 
of SMA have been finally discovered, many drugs [including serine–
arginine-rich proteins, topoisomerase inhibitors, antisense oligonucle-
otides (ASOs) and histone deacetylase inhibitors] have been developed, 
mainly aimed at modifying SMN2 splicing: despite some encouraging 
preliminary results, many of them also showed disadvantages [as tox-
icity, short half-life, insufficient specificity, inefficacy (Lunn and Wang, 
2008)], motivating the researchers to develop more effective, potent and 
specific molecules.
Looking at the most recent available therapeutic strategies, these are 
still aimed at increasing SMN expression, currently with very promising 
clinical results. Nusinersen, developed by Biogen and Ionis Pharma-
ceuticals, is the first-ever treatment for SMA approved by the Food 
and Drug Administration: it is a potent ASO able to modulate SMN2 
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Figure 1 Summary and hypothesis of the role of autophagy in spinal muscular 
atrophy (SMA).
The figure represents a schematic overview of some results published in Piras et 
al. (2017) and a possible hypothesis explaining the involvement of autophagy in 
neurodegeneration occurring in SMA. LC3-II: Microtubule-associated protein 1 
light chain 3-II.
splicing correction. Nusinersen can be delivered by lumbar puncture 
directly into the cerebrospinal fluid. The performed clinical trials pro-
vided evidence of its efficacy in significantly improving motor functions 
both in the most severe form of SMA (SMAI) and in milder patients 
(SMAII and III) (Mercuri et al., 2018), although the multiple and inva-
sive intrathecal injections can induce adverse side effects. Similar results 
come from AVXS-101, marketed by AveXis: it delivers the SMN1 gene 
using non-replicating self-complementary AAV serotype 9. Compared 
to Nusinersen, AVXS-101 has the great advantage to be delivered by in-
travenous injection. Its safety and efficacy have been proved in a clinical 
trial with SMAI patients, where the treatment assured the achievement 
of several motor milestones and lifespan extension (Tosolini and Sleigh, 
2017).
However, the above listed therapies are merely SMN-dependent 
strategies, although it is now clear that further cellular mechanisms can 
affect the severity of SMA, in addition to SMN reduced expression. Since 
at now none therapeutic strategy aimed at restoring SMN is completely 
effective in arresting the disease progression, it is evident that combina-
torial approaches are needed, keeping in mind the complexity of addi-
tional molecular pathways contributing to SMA pathogenesis. In such 
context autophagy can effectively represent a valid target, possibly in 
combination with gene therapy and ASO approaches.
Moreover, recent studies describe SMA as a multisystem disorder, in 
which in addition to the primary affected cells (i.e., spinal MNs) other 
non-neuronal cells/organs are involved (Hamilton and Gillingwater, 
2013). Once again, the development of synergic treatments aimed i) to 
increase the SMN expression and ii) to prevent the disease progression 
using non-SMN targets and SMN-independent mechanisms, is clearly 
essential. Indeed, as concerns the autophagic activation, the process 
seems altered not only in the MNs as we observed, but also into SMA 
skeletal muscles (Oliván et al., 2016): therefore, the administration of an 
autophagic inhibitor systemically administered could further benefit the 
SMA prognosis.
Finally, despite the promising preliminary results, the ongoing clin-
ical trials with Nusinersen still have some limitations mainly related to 
the strict eligibility criteria applied: since many milder SMA patients 
do not satisfy the requirements necessary for inclusion in gene ther-
apy trials, alternative treatments should be rapidly provided for such 
individuals.
Therefore, in conclusion, for all these reasons, therapies targeting 
other molecular pathways (such as the autophagic process) are strongly 
required, alone or in combination with the emerging gene therapy and 
ASO approaches (Figure 2B), in order to assure the most effective treat-
ment to all the SMA patients.
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Comments to authors: In this manuscript, the authors introduced a new concept of 
inhibiting autophagy could be a potential therapeutic treatment for SMA. Authors brief-
ly introduced the disease SMA and the role of autophagy in neuronal physiology and 
pathology. They reported their previous work on this topic as well: using 3-MA to inhibit 
autophagy in a widely accepted SMA model, effectively reduced apoptotic cell death in 
the spinal cord and increased the lifespan of SMA animals. In future prospective, they 
introduced recent studies on treatment of SMA including the discoveries from their 
group and other groups.
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Figure 2 Current state and future therapeutic approaches.
(A) The figure indicates our preclinical strategy in the treatment of spinal 
muscular atrophy (SMA). Intracerebroventricular (ICV) administration of an 
autophagy inhibitor, 3-methyladenine (3-MA), delays motor neuron (MN) de-
generation in the lumbar spinal cord, supports motor behavioral performance 
and extends lifespan of SMA pups. (B) Combinational strategies based on anti-
sense oligonucleotides (ASOs) targeting i) key genes of autophagy (e.g., Beclin 1) 
and ii) survival motor neuron (SMN) alternative splicing (e.g., Nusinersen), are 
aimed to reduce the autophagic vesicle (AV) accumulation and to increase the 
production of full length form of SMN (FL-SMN). 
